NGS abbreviates drug discovery timelines.
To prepare for emerging mRNA technologies, it is necessary to adapt fill/finish and cold chain capabilities.
Basic principles of physiologically-based pharmacokinetic (PBPK) modeling and its impact in streamlining the drug development process are reviewed.
A structured assessment process can determine compliance to lifecycle process-validation requirements for biopharmaceuticals.
Stable cell line development can benefit from applying integrated analytical technologies.
*** Live: Wednesday, November 11, 2020 | 8:30 AM EDT – 4:00 PM EDT *** 2020 Bio/Pharma Virtual Congress: Join Pharmaceutical Technology® and BioPharm International® for this online event that will explore the latest developments in formulation, manufacturing, and innovative drug dosage forms, as well as detailed discussions about crucial topics impacting the industry. ***On demand available after final airing until 11/11/2021***
The IQ Consortium marks a decade of impactful innovation of collaboration through a network of pharmaceutical companies driving change for the bio/pharmaceutical industry.
Data from migration kinetics studies can be used to develop models that predict levels of leachables and extractables at different temperatures and time points.
Modular and replication strategies are being utilized to meet growing demand for CDMO facilities.
In this paper, the authors lay out some commonly accepted HCP analytical methods, the challenges of HCP assay, and provide recommendations on what can easily be accomplished in-house and when it may be better to outsource.
Innovations in downstream processing accelerate development, enhance efficiency, and promote sustainability.
AFI representatives of the process validation working group explore and define key elements for an enhanced approach to process validation for sterile liquid and freeze-dried forms.
The Vi-CELL BLU automates the widely accepted trypan blue dye exclusion method for cell viability that has historically been performed with a light microscope, pipette, and a hemacytometer.
Through the integration of human expertise, artificial intelligence, and automation robotics, bio/pharma companies can more efficiently target drug discovery efforts with bigger payoff.
Controlling certain atmospheric conditions in a closed NGI processing chamber can reduce bioburden without disinfectants.
Improving the flexibility of cell line development through utilization of platform approaches and suitable partnerships can reduce potential bottlenecks in the development pathway of novel biologics.
This article introduces the requirements for a biosimilar license in Brazil and addresses questions about their quality, safety, and efficacy.
An industrial biotechnology company in Denmark required more rigorous control measures to ensure a high level of bio-decontamination in its facility. An automated hydrogen peroxide vapor service from Bioquell was selected.
Digital transformation allows for smarter and connected biomanufacturing operations.
CDMOs are actively exploring and leveraging both new and existing technologies to streamline the cell-line development process at every step.
In this article, a simple chromatographic model is proposed that is capable of predicting the impact of pH and ionic strength on HIC chromatograms.
A novel mathematical approach for fitting concentration-response curves is proposed that offers a more accurate estimation of potency data.
A task force details its findings of the risks associated with using convalescent plasma using failure mode and effects analysis
Scenario modeling informs planning for current and future manufacturing needs.
This event offers knowledge sharing, relationship building, and deal-making for biotech and pharmaceutical companies to advance commercialization of advanced therapies.
Therapeutic protein aggregates can be characterized using image analysis algorithms coupled with microscopy techniques.